U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
作者： Jonathan D. Berman
DOI: 10.1086/515086
关键词:
摘要:
oup.com
oxfordjournals.org
sci-hub.se 参考文章(9)
Philippe Desjeux, None, Leishmaniasis: Public health aspects and control Clinics in Dermatology. ,vol. 14, pp. 417- 423 ,(1996) , 10.1016/0738-081X(96)00057-0
R. Badaro, K. Weerasuriya, C. P. Thakur, L. Pang, K. Behbehani, F. Kuzoe, R. Davidson, J. D. Berman, A. D. M. Bryceson, K. M. Wasunna, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of The World Health Organization. ,vol. 76, pp. 25- 32 ,(1998)
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. QJM: An International Journal of Medicine. ,vol. 87, pp. 75- 81 ,(1994) , 10.1093/OXFORDJOURNALS.QJMED.A068903
Shyam Sundar, Nutan K Agrawal, Prabhat R Sinha, Gary S Horwith, Henry W Murray, None, Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine. ,vol. 127, pp. 133- 137 ,(1997) , 10.7326/0003-4819-127-2-199707150-00007
R. N. Davidson, L. di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. di Caprio, R. J. Wilkinson, A. D. M. Bryceson, Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome) Clinical Infectious Diseases. ,vol. 22, pp. 938- 943 ,(1996) , 10.1093/CLINIDS/22.6.938
R. Dietze, E. P. Milan, J. D. Berman, M. Grogl, A. Falqueto, T. F. Feitosa, K. G. Luz, F. A. B. Suassuna, L. A. C. Marinho, G. Ksionski, Treatment of Brazilian Kala-Azar with a Short Course of Amphocil (Amphotericin B Cholesterol Dispersion) Clinical Infectious Diseases. ,vol. 17, pp. 981- 986 ,(1993) , 10.1093/CLINIDS/17.6.981
Andrea Meyerhoff, U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases. ,vol. 28, pp. 42- 48 ,(1999) , 10.1086/515085
Thomas J. Walsh, Vijay Yeldandi, Maureen McEvoy, Corina Gonzalez, Stephen Chanock, Alison Freifeld, Nita I. Seibel, Patricia O. Whitcomb, Paul Jarosinski, Garry Boswell, Ihor Bekersky, Ala Alak, Donald Buell, John Barret, Wyndham Wilson, Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 2391- 2398 ,(1998) , 10.1128/AAC.42.9.2391
T K Jha, P Olliaro, C P N Thakur, T P Kanyok, B L Singhania, I J Singh, N K P Singh, S Akhoury, S Jha, D. N J Lockwood, Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India Commentary: Some good news for treatment of visceral leishmaniasis in Bihar BMJ. ,vol. 316, pp. 1200- 1205 ,(1998) , 10.1136/BMJ.316.7139.1200